{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:18:05Z","timestamp":1792786685668,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"IDIBELL","id":[{"id":"https:\/\/ror.org\/0008xqs48","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jconrel.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T12:51:37Z","timestamp":1467636697000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery"],"prefix":"10.1016","volume":"237","author":[{"given":"Luis Alfonso","family":"Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela N.","family":"Condezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Arias-Badia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"San Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2016.07.004_bb0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.jconrel.2016.07.004_bb0010","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/v7112923","article-title":"Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications","volume":"7","author":"Uusi-Kerttula","year":"2015","journal-title":"Viruses"},{"issue":"50","key":"10.1016\/j.jconrel.2016.07.004_bb0015","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"32","key":"10.1016\/j.jconrel.2016.07.004_bb0020","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jconrel.2016.07.004_bb0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jconrel.2016.07.004_bb0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.jconrel.2016.07.004_bb0035","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jconrel.2016.07.004_bb0040","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jconrel.2016.07.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082716","article-title":"Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo","volume":"9","author":"Prill","year":"2014","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.jconrel.2016.07.004_bb0050","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1128\/JVI.79.15.9694-9701.2005","article-title":"Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity","volume":"79","author":"Lemckert","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2016.07.004_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.55.091902.104344","article-title":"Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors","volume":"55","author":"Shiver","year":"2004","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2016.07.004_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033920","article-title":"Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses","volume":"7","author":"Bruder","year":"2012","journal-title":"PLoS One"},{"issue":"7090","key":"10.1016\/j.jconrel.2016.07.004_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jconrel.2016.07.004_bb0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/JVI.02889-14","article-title":"Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment","volume":"89","author":"Scherer","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2016.07.004_bb0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2014.03.013","article-title":"A clinical update of using albumin as a drug vehicle \u2014 a commentary","volume":"190","author":"Kratz","year":"2014","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2016.07.004_bb0080","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain","volume":"286","author":"Andersen","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"38","key":"10.1016\/j.jconrel.2016.07.004_bb0085","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","article-title":"Albumin binding as a general strategy for improving the pharmacokinetics of proteins","volume":"277","author":"Dennis","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.jconrel.2016.07.004_bb0090","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","article-title":"Albumin as a versatile platform for drug half-life extension","volume":"1830","author":"Sleep","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.jconrel.2016.07.004_bb0095","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1074\/jbc.M109943200","article-title":"Structure, specificity, and mode of interaction for bacterial albumin-binding modules","volume":"277","author":"Johansson","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2016.07.004_bb0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1110\/ps.02802","article-title":"Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin","volume":"11","author":"Linhult","year":"2002","journal-title":"Protein Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2016.07.004_bb0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/protein\/gzm061","article-title":"A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G","volume":"20","author":"Stork","year":"2007","journal-title":"Protein Eng. Des. Sel."},{"issue":"11","key":"10.1016\/j.jconrel.2016.07.004_bb0110","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses","volume":"18","author":"Rojas","year":"2010","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2016.07.004_bb0115","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/bi00120a023","article-title":"Localization of the binding site for streptococcal protein G on human serum albumin. Identification of a 5.5-kilodalton protein G binding albumin fragment","volume":"31","author":"Falkenberg","year":"1992","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.jconrel.2016.07.004_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1432-1033.1990.tb19315.x","article-title":"Species-dependent binding of serum albumins to the streptococcal receptor protein G","volume":"193","author":"Nygren","year":"1990","journal-title":"Eur. J. Biochem."},{"issue":"10","key":"10.1016\/j.jconrel.2016.07.004_bb0125","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1586\/14760584.2013.836912","article-title":"Oncolytic vaccines","volume":"12","author":"Elsedawy","year":"2013","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/j.jconrel.2016.07.004_bb0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2016.07.004_bb0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/protein\/gzm067","article-title":"Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs","volume":"21","author":"Holt","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"issue":"2","key":"10.1016\/j.jconrel.2016.07.004_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":"SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients","volume":"2","author":"Desai","year":"2009","journal-title":"Transl. Oncol."},{"issue":"34","key":"10.1016\/j.jconrel.2016.07.004_bb0145","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2016.07.004_bb0150","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.jconrel.2016.07.004_bb0155","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/JVI.70.4.2116-2123.1996","article-title":"Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes","volume":"70","author":"Gall","year":"1996","journal-title":"J. Virol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2016.07.004_bb0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-1759(98)00112-4","article-title":"Use of an albumin-binding domain for the selective immobilisation of recombinant capture antibody fragments on ELISA plates","volume":"218","author":"Konig","year":"1998","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.jconrel.2016.07.004_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs","volume":"24","author":"Alonso-Padilla","year":"2016","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2016.07.004_bb0170","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.01392-12","article-title":"Circulating antibodies and macrophages as modulators of adenovirus pharmacology","volume":"87","author":"Khare","year":"2013","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.jconrel.2016.07.004_bb0175","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.jconrel.2016.07.004_bb0180","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1089\/10430340050083289","article-title":"Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy","volume":"11","author":"Chen","year":"2000","journal-title":"Hum. Gene Ther."},{"issue":"21","key":"10.1016\/j.jconrel.2016.07.004_bb0185","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-04-0765","article-title":"Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model","volume":"10","author":"Tsai","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2016.07.004_bb0190","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.jconrel.2016.07.004_bb0195","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2016.07.004_bb0200","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression","volume":"21","author":"Rodriguez-Garcia","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2016.07.004_bb0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/gt.2011.106","article-title":"Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD","volume":"19","author":"Rojas","year":"2012","journal-title":"Gene Ther."},{"issue":"15","key":"10.1016\/j.jconrel.2016.07.004_bb0210","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.onc.1202118","article-title":"Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells","volume":"17","author":"Villanueva","year":"1998","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jconrel.2016.07.004_bb0215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"Biotechniques"},{"issue":"2","key":"10.1016\/j.jconrel.2016.07.004_bb0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","article-title":"CTFFIND4: fast and accurate defocus estimation from electron micrographs","volume":"192","author":"Rohou","year":"2015","journal-title":"J. Struct. Biol."},{"issue":"5995","key":"10.1016\/j.jconrel.2016.07.004_bb0225","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1126\/science.1187433","article-title":"Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks","volume":"329","author":"Liu","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2016.07.004_bb0230","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/jsbi.1999.4174","article-title":"EMAN: semiautomated software for high-resolution single-particle reconstructions","volume":"128","author":"Ludtke","year":"1999","journal-title":"J. Struct. Biol."},{"issue":"13","key":"10.1016\/j.jconrel.2016.07.004_bb0235","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2016.07.004_bb0240","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/gt.2014.52","article-title":"iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy","volume":"21","author":"Puig-Saus","year":"2014","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2016.07.004_bb0245","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/gt.2015.41","article-title":"Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity","volume":"22","author":"Rodriguez-Garcia","year":"2015","journal-title":"Gene Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T05:02:36Z","timestamp":1600837356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916304291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":49,"alternative-id":["S0168365916304291"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}